Eli Lilly Q1 revenue grows 56% on GLP-1 sales
Shares rose after the quarter, with incretin products driving the top-line increase.
TR
By Tom Reyes · Markets Editor
Apr 30 03:00 ETSource: Yahoo Finance
The wire
- 01Lilly reported first-quarter revenue growth of 56%, attributed to GLP-1 drug sales, and the stock climbed on the result.
- 02Sustained incretin demand shapes supply and pricing expectations for pharmacies and clinics dispensing branded tirzepatide.
- 03Segment-level detail and full-year guidance implications are in the company's filings rather than this report.
From the source
Read at finance.yahoo.comEli Lilly stock soars after Q1 earnings as revenue grows 56% on strength of GLP-1 drug sales